Company: EVGN
Filing Date: 2025-03-28
Form Type: POS AM
Source: 0001178913-25-001096
Chunk: 6

Company: Evogene Ltd.
Filing Date: 2025-03-28
Form: POS AM
Chunk 6
---
 representation as to the accuracy of that information. Unless otherwise indicated, we have translated NIS amounts into U.S. dollars at an exchange rate of NIS 3.647 to $1.00, the representative exchange rate reported by the Bank of Israel on December 31, 2024. PROSPECTUS SUMMARY This section summarizes certain of the information that is contained in this prospectus or the documents incorporated by reference herein, and this summary is qualified in its entirety by that more detailed information. This summary may not contain all of the information that may be important to you. We urge you to carefully read this entire prospectus and the documents incorporated by reference herein, including the 2024 annual report, which is incorporated by reference herein. As an investor or prospective investor, you should review carefully the more detailed information that appears later in this prospectus and the information incorporated by reference in this prospectus, including the sections entitled “Risk Factors” herein and in Item 3.D of the 2024 annual report. Our Company We are a leading computational biology company aiming to revolutionize life-science product development across several market segments, including human health, agriculture, and other industries, by utilizing cutting-edge computational technologies. The main challenge in product development in the life science industry is finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria to reach successful products. We believe that by utilizing an advanced computational biology platform to identify the most promising candidates addressing multiple development challenges toward successful life-science products, we can increase the probability of success while reducing time and cost. To achieve this mission, we established our unique Computational Predictive Biology, or CPB, platform, leveraging big data and artificial intelligence and incorporating deep multidisciplinary understanding in life sciences. The CPB platform is the basis for three technology engines; each focused on the direction and acceleration of the discovery and development of products based on one of the following core components: Microbes - MicroBoost AI ; Small molecules - ChemPass AI ; and Genetic elements - GeneRator AI. In 2024, we emphasized our research and development efforts on MicroBoost AIand ChemPass AI. During 2025 we intend to direct our efforts by focusing further on the use of our ChemPass AItech-engine in the field of AI powered drug discovery in the pharma market segment. We intend to continue the support and development of the MicroBoost AIand GeneRator AItech-engines based on the needs of our subsidiaries, with their funding. We use our